Sega Pharmaceutical Co., Ltd., founded in 2007, belonging to Tianjin Pharmaceutical Holdings(TJPH), invests 70 million USD to construct our API manufacturing site, which covers 199 thousand sq meters.
As the key enterprise of the APIs base of Tianjin, we supplies the latest state of the art technology to manufacture APIs and pharmaceutical intermedistes, especially focuses on antivirus APIs, such as lamivudine. As one of the largest lamivudine manufacturers in China, our capacity is 200 tons per year. Although our capacity is large, we have the complete QC team and apply the internal control standard, which is stricter than the specs on USP30, to guarantee our product's continuously high quality .
Our R&D team is consisting of highly pharmaceutical experienced Doctors and many well educated Masters and Bachelors, who have taken a lot effort to optimize the synthesis process to reduce the cost and enhance the quality of lamivudine. Therefore, we boast our competitive advantages on process, cost, quality control of lamivudine, and can provide our products which can meet the most particular demand to our customers.
As the key enterprise of the APIs base of Tianjin, we supplies the latest state of the art technology to manufacture APIs and pharmaceutical intermedistes, especially focuses on antivirus APIs, such as lamivudine. As one of the largest lamivudine manufacturers in China, our capacity is 200 tons per year. Although our capacity is large, we have the complete QC team and apply the internal control standard, which is stricter than the specs on USP30, to guarantee our product's continuously high quality .
Our R&D team is consisting of highly pharmaceutical experienced Doctors and many well educated Masters and Bachelors, who have taken a lot effort to optimize the synthesis process to reduce the cost and enhance the quality of lamivudine. Therefore, we boast our competitive advantages on process, cost, quality control of lamivudine, and can provide our products which can meet the most particular demand to our customers.
